Roles and Therapeutic Potential of the SLC Family in Prostate Cancer-literature Review

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2025 Feb 18

PMID 39966814

Authors

Yuanzhi Fu

Junhao Chen

Xingcheng Zhu

Mingxia Ding

Haifeng Wang

Shi Fu

Affiliations

Soon will be listed here.

Abstract

Prostate cancer (PCa) is one of the most common malignancies in men worldwide. Despite advances in treatment, many patients develop resistance to conventional therapies. Solute carrier (SLC) proteins, as transmembrane transporters, have recently emerged as potential therapeutic targets due to their role in tumor metabolism and progression. This review summarizes the key roles of six SLC proteins in PCa, including their involvement in metabolic reprogramming, regulation of signaling pathways, and effects on the tumor microenvironment. Although targeting of SLC family members in prostate cancer remains an underexplored area, the growing body of evidence suggests that it holds potential for future development.

References

Vaarala M, Hirvikoski P, Kauppila S, Paavonen T . Identification of androgen-regulated genes in human prostate. Mol Med Rep. 2012; 6(3):466-72. PMC: 3493087. DOI: 10.3892/mmr.2012.956. View

Vungutur V, Yu S, McCabe S, Fung C, Zhao N . A simple and highly reproducible method for the detection of erythrocyte membrane ZIP metal transporters by immunoblotting. Methods Enzymol. 2023; 687:87-102. PMC: 10755855. DOI: 10.1016/bs.mie.2023.04.019. View

Goodman C . The role of mTORC1 in regulating protein synthesis and skeletal muscle mass in response to various mechanical stimuli. Rev Physiol Biochem Pharmacol. 2014; 166:43-95. DOI: 10.1007/112_2013_17. View

Elmetwalli A, Abdel-Monem M, El-Far A, Ghaith G, Albalawi N, Hassan J . Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment. Med Oncol. 2024; 41(5):106. PMC: 10995097. DOI: 10.1007/s12032-024-02330-8. View

Chen J, Zhao S, Nakada K, Kuge Y, Tamaki N, Okada F . Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol. 2003; 162(4):1283-91. PMC: 1851236. DOI: 10.1016/s0002-9440(10)63924-7. View

Ljungholm P, Ermund A, Soderlund Garsveden M, Pettersson V, Gustafsson J . The anion exchanger slc26a3 regulates colonic mucus expansion during steady state and in response to prostaglandin E, while Cftr regulates de novo mucus release in response to carbamylcholine. Pflugers Arch. 2024; 476(8):1209-1219. PMC: 11271379. DOI: 10.1007/s00424-024-02975-4. View

Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B . The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019; 698:120-128. DOI: 10.1016/j.gene.2019.02.076. View

Payen V, Hsu M, Radecke K, Wyart E, Vazeille T, Bouzin C . Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter. Cancer Res. 2017; 77(20):5591-5601. DOI: 10.1158/0008-5472.CAN-17-0764. View

Ouyang J, Hu Z, Tong J, Yang Y, Wang J, Chen X . Construction and evaluation of a nomogram for predicting survival in patients with lung cancer. Aging (Albany NY). 2022; 14(6):2775-2792. PMC: 9004553. DOI: 10.18632/aging.203974. View

10.

Li T, Wang J, Feng L, Zhou Q, Xie Q, Shen Y . Discovery of novel thiophene-3-carboxamide derivatives as potential VEGFR-2 inhibitors with anti-angiogenic properties. Bioorg Chem. 2024; 147:107358. DOI: 10.1016/j.bioorg.2024.107358. View

11.

Nalecz K . Amino Acid Transporter SLC6A14 (ATB) - A Target in Combined Anti-cancer Therapy. Front Cell Dev Biol. 2020; 8:594464. PMC: 7609839. DOI: 10.3389/fcell.2020.594464. View

12.

Reyner E, Sevidal S, West M, Clouser-Roche A, Freiwald S, Fenner K . In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions. Drug Metab Dispos. 2013; 41(8):1575-83. DOI: 10.1124/dmd.113.051193. View

13.

Kim J, Hwang K, Lee H, Kim H . Systematic Analysis of Cellular Signaling Pathways and Therapeutic Targets for SLC45A3:ERG Fusion-Positive Prostate Cancer. J Pers Med. 2022; 12(11). PMC: 9693845. DOI: 10.3390/jpm12111818. View

14.

Yang F, Lee G, Fan Y . Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism. Angiogenesis. 2024; 27(3):333-349. PMC: 11303583. DOI: 10.1007/s10456-024-09913-z. View

15.

Lin H, Park H, Radlein S, Mahajan N, Sellers T, Zachariah B . Protein expressions and genetic variations of SLC5A8 in prostate cancer risk and aggressiveness. Urology. 2011; 78(4):971.e1-9. PMC: 3190039. DOI: 10.1016/j.urology.2011.04.055. View

16.

Benaiges E, Ceperuelo-Mallafre V, Guaita S, Maymo-Masip E, Madeira A, Gomez D . Survivin/BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Head Neck. 2024; 46(7):1752-1765. DOI: 10.1002/hed.27651. View

17.

Vaz C, Alves M, Marques R, Moreira P, Oliveira P, Maia C . Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol. 2012; 44(11):2077-84. DOI: 10.1016/j.biocel.2012.08.013. View

18.

Luo Y, Yang Z, Yu Y, Zhang P . HIF1α lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in prostate cancer. Int J Biol Macromol. 2022; 222(Pt B):2225-2243. DOI: 10.1016/j.ijbiomac.2022.10.014. View

19.

Modi P, Herrel L, Kaufman S, Yan P, Borza T, Skolarus T . Urologist Practice Structure and Spending for Prostate Cancer Care. Urology. 2019; 130:65-71. PMC: 6660353. DOI: 10.1016/j.urology.2019.03.029. View

20.

Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q . Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021; 6(1):218. PMC: 8190181. DOI: 10.1038/s41392-021-00641-0. View